Apremilast - 3SBio

Drug Profile

Apremilast - 3SBio

Alternative Names: AP 506

Latest Information Update: 28 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator 3SBio
  • Class Anti-inflammatories; Antineoplastics; Antipsoriatics; Isoindoles; Phthalimides; Small molecules; Sulfones
  • Mechanism of Action Interleukin 23 inhibitors; Tumour necrosis factor alpha inhibitors; Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Psoriatic arthritis

Most Recent Events

  • 27 Sep 2016 Chemical structure information added
  • 22 Sep 2016 Phase-I clinical trials in Psoriatic arthritis in China before September 2016 (3SBio pipeline, September 2016)
  • 01 Mar 2016 Preclinical trials in Psoriatic arthritis in China before March 2016 (3SBio website, September 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top